What factors drove the changes in Pelthos Therapeutics's revenue and profit?

What is Pelthos Therapeutics's gross profit margin?

What does Pelthos Therapeutics do and what are its main business segments?

What guidance did Pelthos Therapeutics's management provide for the next earnings period?

What is Pelthos Therapeutics's latest dividend and current dividend yield?

What is the market's earnings forecast for Pelthos Therapeutics next quarter?

Did Pelthos Therapeutics beat or miss consensus estimates last quarter?

What were the key takeaways from Pelthos Therapeutics’s earnings call?

- **ZELSUVMI Success**: 129% prescription growth (Q3 to Q4 2025) and 28% revenue increase, with 99% Medicaid coverage.
- **New Product Acquisitions**: Xepi (impetigo) and Xeglyze (lice) set for 2027 launches, enhancing commercial leverage.
- **Financial Improvement**: 22% reduction in operating loss, $18M cash balance, and $30M term debt for 2026 growth.
- **Profitability Outlook**: ZELSUVMI expected to turn profitable by end-2026, with GTN margins stabilizing at mid-30%.

**【CEO Summary Section】**
- ZELSUVMI achieved a 129% increase in prescriptions (2,716 to 6,232 units) from Q3 to Q4 2025, driving net product revenue growth of 28% ($7.1M to $9.1M).
- Acquired Xepi (FDA-approved topical treatment for impetigo) and Xeglyze (FDA-approved treatment for head lice), both expected to launch in 2027, leveraging existing commercial infrastructure.
- Reduced quarterly operating loss by 22% (from $15.4M to $12.0M) and EBITDA loss by 22% (from $11.5M to $9.0M), with a strengthened cash balance of $18.0M.

**【CFO Financial Commentary】**
- Net product revenue for Q4 2025: $9.1M (28% YoQ growth), with GTN (gross to net) at 28.7%, expected to rise to mid-30% due to PBM contracts and Medicaid discounts.
- SG&A expenses decreased 5% YoQ ($18.5M to $17.6M), with $30M term debt issuance providing runway for 2026 launches.
- Royalty obligations totaled $1.6M in Q4, tied to ZELSUVMI sales and Xepi/Xeglyze launches.

**【Q&A Highlights】**
- **Competitive Dynamics**: ZELSUVMI positioned as first-line monotherapy, with no counter-detailing against Ycanth; 99% Medicaid coverage and 59% commercial insurance access.
- **Growth Drivers**: Expansion of 14 sales reps in key markets, YouTube commercial (4.5M views), and AAD conference engagement.
- **Profitability Path**: Expect ZELSUVMI to become profitable by end-2026, with full-year 2026 revenue growth driven by ZELSUVMI and new product launches.
- **Seasonality**: Q2/Q3 2026 expected to see higher volumes due to warmer weather and increased patient visits,2026.

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

- **ZELSUVMI launch success**: $7.1M Q3 revenue, 41% month-over-month growth in October prescriptions.
- **Sales force expansion**: Adding 14 reps to cover major cities, targeting 64 reps by Q1 2026.
- **Xepi acquisition**: $18M convertible notes financing to accelerate launch of complementary impetigo treatment.
- **Financial targets**: Cash flow breakeven by end-2026, $175M peak ZELSUVMI revenue by 2028.
- **Market dynamics**: No seasonal trends, but holiday-related office closures may impact Q4 growth.

**【CEO Opening Remarks】**
- Announced successful acquisition of Pelthos business, NYSE listing, and $50M PIPE financing to support ZELSUVMI launch.
- Launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum (MC), generating $7.1M in Q3 net product revenue.
- Acquired Xepi, a topical treatment for impetigo, with $18M convertible notes financing to accelerate commercialization.
- Projected cash flow breakeven by end of 2026, targeting $175M peak revenue for ZELSUVMI by 2028.

**【Sai Rangarao - ZELSUVMI Launch Metrics】**
- Q3 shipments: 4,900 units to wholesalers, 3,000 to pharmacies; 2,716 prescriptions from 1,169 unique prescribers.
- October prescriptions up 41% YoM, with 516 units dispensed in last week of Q3 (annualized $52M run rate).
- GTN rate 25.3% in Q3, expected to rise to mid-30% by Q1 2026.
- Expanded sales force from 50 to 64 reps by mid-January to cover major metropolitan areas.

**【Frank Knuettel - Financial Highlights】**
- Q3 2025: $7.1M net product revenue, $16.2M GAAP net loss, $1.83 EPS (as-converted basis).
- COGS $2.3M (includes inventory step-up costs); normalized COGS expected by mid-2026.
- SG&A expenses $19.6M (includes $3.2M non-cash charges, $1M one-time merger costs).
- $14.2M cash on hand, $8M A/R; $18M convertible notes financing closed in Q3.

**【Q&A Highlights】**
- **Prescriber behavior**: 60% of HCPs wrote 1 script, 40% wrote 2+; 3 HCPs wrote 22-27 scripts.
- **Holiday impact**: Acute treatment requires in-office prescription, expect softening in Q4.
- **Refill rates**: 1.2 units per patient average; 3 units needed for full 12-week course.
- **Sales force profitability**: All 50 reps covered costs within 9 weeks; new 14 reps expected to breakeven quickly.
- **Price strategy**: No commercial contracts, cautious about future price increases.
- **Pipeline**: Evaluating additional NitroCil-based products; no immediate plans for new acquisitions beyond Xepi.

Actual		-3.21	-5.38	-5.3	-3.76
Forecast		-2.9	-5.82	-0.575	-3.256
Surprise	0.00%	-10.69%	+7.56%	-821.74%	-15.48%

Actual	--	150.00K	0	7.41M	10.00M
Forecast	--	--	0	4.39M	10.44M
Surprise	0.00%	0.00%	0.00%	+68.72%	-4.21%

PTHS

PTHS fundamentals

PTHS Q4 2025 Earnings

Earnings Call

You can ask Aime

PTHS

PTHS fundamentals

PTHS Q4 2025 Earnings

Earnings Call

PTHS Earnings Call Summary for Q4/20258:00 AM on Mar 19, 2026

PTHS Earnings Call Summary for Q3/20258:00 AM on Nov 13, 2025

PTHS Earnings Call Summary for Q2/2025 Mar 25, 2026

PTHS Earnings Call Summary for Q1/2025 Mar 25, 2026

PTHS Earnings Call Summary for Q4/2024 Mar 25, 2026

You can ask Aime